# Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™

> **NCT02937740** · PHASE4 · COMPLETED · sponsor: **Acerus Pharmaceuticals Corporation** · enrollment: 117 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** NATESTO Testosterone Nasal Gel

## Key facts

- **NCT ID:** NCT02937740
- **Lead sponsor:** Acerus Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-10
- **Final completion:** 2017-11
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2019-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937740, "Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02937740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*